Within Scripps, PageScience has identified a handful of contextual health categories, like diabetes, allergies and asthma, to offer advertisers.
Traditionally, pharma TV ads can be lengthy in order to accommodate fair balance information – the fine print about medications that marketers are obliged to disclose. The longer TV ads can run between 60 and 75 seconds, but the cutoff for PageScience’s pre-roll videos is 60 seconds. To comply with fair balance information, Sly said Scripps is running companion display ads, and only accepts spots longer than 60 seconds if the videos are skippable.
Despite regulatory hurdles for health marketing via display advertising, pre-roll video ads actually make pharma advertising easier, Jennings claimed, because targeted can be tailored to a broader audience. Pharma advertisers are looking to run more general ads that can be bucketed to broad health and wellness interests, he said. But if that’s true, advertisers may wonder if their messages truly are reaching the right audience.
“The standards that we’re held to for display with page-level scoring is a broader target when you get to video,” he explained. “Advertisers are looking for demo targeting or targeting against notions of lifestyle. It doesn’t have to be as contextual as banner targeting.”
For metrics, PageScience measures completion rates, but Jennings couldn’t share specific figures around early results. For pharma advertisers interested in digital video, Jennings explained that the format work best for predominant conditions. It’s fairly easy to target prevalent health conditions like diabetes or allergies, he said, but ensuring reach against a niche health condition is more difficult.
Sly declined to quantify Scripps’ increase in revenue due to the partnership but said he is encouraged by what the firm has seen so far.
“High-quality preroll video is in short supply,” he said. “There’s definitely great demand for it.”
“What’s encouraging about this partnership is that we’re giving pharma advertisers a way to reach a new target audience,” Sly added. “For Scripps, it’s an opportunity to grow share of revenue. For the pharma advertisers, it’s a opportunity to reach high-quality audiences with a different platform.”